Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson vELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide operational (constant-currency) growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2020
-45.8%
Period ended Jan 3, 2021
Change on a year earlier
-15.7 pts
-30.1% in FY2019
History
4 years
Since FY2017
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Jan 3, 2021 | -45.8% | -15.7 pts | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
| FY2019 | Dec 29, 2019 | -30.1% | -28.1 pts | Form 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗ |
| FY2018 | Dec 30, 2018 | -2.0% | +6.8 pts | Form 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗ |
| FY2017 | Dec 31, 2017 | -8.8% | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up velcade (bortezomib) [reported separately through fy2020q4] — worldwide operational (constant-currency) growth yoy (%)
Cite this data
StockData. (2026). Johnson & Johnson VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide operational (constant-currency) growth YoY (%) (%), annual FY2017–FY2020 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_velcade_ops_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.